Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the offering, the company issued an aggregate of 24,264,706 units of the company, each at a price of US$0.34, … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering